Your browser doesn't support javascript.
loading
Hypopharyngeal carcinoma in Finland from 2005 to 2014: outcome remains poor after major changes in treatment.
Keski-Säntti, Harri; Luukkaa, Marjaana; Carpén, Timo; Jouppila-Mättö, Anna; Lehtiö, Kaisa; Mäenpää, Hanna; Vuolukka, Kristiina; Vahlberg, Tero; Mäkitie, Antti.
Afiliação
  • Keski-Säntti H; Department of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Hospital, University of Helsinki, P.O.Box 263, 00029, Helsinki, Finland. harri.keski-santti@hus.fi.
  • Luukkaa M; Department of Oncology, Turku University Hospital and University of Turku, Turku, Finland.
  • Carpén T; Department of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Hospital, University of Helsinki, P.O.Box 263, 00029, Helsinki, Finland.
  • Jouppila-Mättö A; Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Lehtiö K; Department of Pathology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Mäenpää H; Department of Otorhinolaryngology-Head and Neck Surgery, Kuopio University Hospital, Kuopio, Finland.
  • Vuolukka K; Department of Oncology, Oulu University Hospital and University of Oulu, Oulu, Finland.
  • Vahlberg T; Department of Oncology, Tampere University Hospital, Tampere, Finland.
  • Mäkitie A; Department of Oncology, Kuopio University Hospital, Kuopio, Finland.
Eur Arch Otorhinolaryngol ; 280(3): 1361-1367, 2023 Mar.
Article em En | MEDLINE | ID: mdl-36094562
PURPOSE: Hypopharyngeal carcinoma (HPC) is typically diagnosed at late stages, the patients tend to have serious co-morbidities, distant relapses are frequent, and the related mortality remains high. The treatment paradigm of HPC has remarkably changed from primary surgical approach toward definitive, platinum-based concomitant chemoradiotherapy (CRT). Our aim was to analyze the HPC treatment approaches and outcome in a nationwide series and to make a comparison with a previously published corresponding nationwide patient cohort from the period 1990-1999. METHODS: We retrospectively reviewed all patients diagnosed with HPC at the five university hospitals in Finland between 2005 and 2014. RESULTS: The cohort comprised 231 patients. Treatment with curative intent was offered for 175 (76%) patients and consisted of definitive radiotherapy (RT) or CRT in 156 (89%) patients, while 20 (11%) patients had primary surgery with or without adjuvant RT or CRT. The 5-year estimates for overall survival (OS) and disease specific survival (DSS) for the whole study group were 22.7% and 36.5%, respectively. For patients treated with curative intent, the 5-year estimates for OS and DSS were 29.4% and 44.3%, respectively. CONCLUSIONS: The treatment approach of HPC in Finland has changed thoroughly, as in the 1990s, 63% of HPC patients with curative treatment intent underwent primary surgery with or without RT, while in the current study, the primary treatment approach was non-surgical in 89% of the patients. However, the survival figures have not changed and remain dismal, but most of the few surviving patients now can retain their larynx.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Neoplasias Hipofaríngeas / Neoplasias de Cabeça e Pescoço Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Neoplasias Hipofaríngeas / Neoplasias de Cabeça e Pescoço Idioma: En Ano de publicação: 2023 Tipo de documento: Article